a year ago

Hornet Therapeutics Raises Seed Funding to Develop EBV Treatments

  • Hornet Therapeutics, a UK-based biotech company, has emerged from stealth with seed funding from 4BIO Capital

  • The company is developing treatments for EBV-driven pathologies, including post-transplant lymphoproliferative disorder (PTLD)

  • Hornet's lead drug candidate, HTX-201, has shown promising results in preclinical studies and is expected to enter phase 1/2 clinical trials within the next 12-18 months.

      • ProblemHealthcare

      "Hornet Therapeutics aims to address the issue of Epstein-Barr Virus (EBV) driving various pathologies, such as lymphomas, by developing treatments that target the virus's exploitation of metabolic pathways in infected B cells."

      Solution

      "Hornet Therapeutics is developing HTX-201, a proprietary IDO-1 inhibitor, to prevent EBV-associated diseases, starting with the prevention of EBV-driven Post-Transplant Lymphoproliferative Disorder (PTLD) in high-risk solid organ transplant recipients."

      Covered on